EGFR and rectal cancer: Subgroup analyses for all patients (Supplemental Fig. S3) and the limited population of patients with middle/low rectal cancer (Supplemental Fig. S4) indicate that patients without metastasectomy showed higher OS in the non-first-line anti-EGFR treatment group than in the first-line group.